SEATTLE--(BUSINESS WIRE)--May 25, 2006--Targeted Genetics Corporation (Nasdaq:TGEND - News) and its academic and corporate collaborators will report data in 14 presentations at the 9th Annual Meeting of the American Society of Gene Therapy (ASGT). The meeting will take place June 1 - June 5 in Baltimore, Maryland. Two presentations will discuss preliminary safety and efficacy data from an ongoing Phase I/II clinical trial of tgAAC94 in patients with inflammatory arthritis, and two additional presentations will describe other advances in the company’s inflammatory disease program. Research conducted by Dr. John Engelhardt, Ph.D., Director of the Center for Gene Therapy, and Professor, Department of Anatomy and Cell Biology, at the University of Iowa, and funded by Targeted Genetics, will be featured as one of the “Top Five Abstracts” at the Presidential Symposium on June 3rd (Abstract # 807). Additional presentations will focus on advances in AAV manufacturing, basic and applied AAV biology and Targeted Genetics’ collaborations in the areas of Huntington’s disease and congestive heart failure.
